Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases

Annals of Oncology

Volumn 12, Issue 2, 2001, Pages 249-254

  Christodoulou, C ^a   Bafaloukos, D ^b   Kosmidis, P ^c   Samantas, E ^d   Bamias, A ^e   Papakostas, P ^f   Karabelis, A ^b   Bacoyiannis, C ^c   Skarlos, D V ^a  

^a ATHENS MEDICAL CENTER   (Greece)

^b METAXA CANCER HOSPITAL   (Greece)

^c HYGEIA HOSPITAL   (Greece)

^d AGII ANARGIRI CANCER HOSPITAL   (Greece)

^e UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^f GR 546 42 T   (Greece)

Author keywords

Alkylating agent; Brain metastases; Temozolomide

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; MITOMYCIN; PACLITAXEL; TEMOZOLOMIDE; VINBLASTINE;

ADULT; AGED; ANOREXIA; ARTICLE; BLOOD TOXICITY; BRAIN METASTASIS; BREAST CANCER; CANCER GROWTH; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DEATH; DIARRHEA; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE; NAUSEA AND VOMITING; NEUROLOGIC EXAMINATION; PERFORMANCE; PHASE 2 CLINICAL TRIAL; PREMEDICATION; PRIORITY JOURNAL; SOLID TUMOR; SURVIVAL TIME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DACARBAZINE; DRUG EVALUATION; FEMALE; HUMANS; MALE; MIDDLE AGED; SAFETY; TREATMENT OUTCOME;

EID: 0035100919     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008354323167     Document Type: Article

References (36)

1. Treatment of meststatic cancer
2. Brain metastases. Histology, multiplicity,surgery, survival
3. Identification of prognostic factors in patient with brain metastases: A review of 1292 patients
4. Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases
5. Prognostic factors in brain metastases: Should patients be selected for a aggressive treatment
6. Prognostic factors derived from recusive partition analysis (RPA) of Radiations Therapy Oncology Group (RTOG) brain metastases trials applied to surgically resected and irradiated brain metastatic cases
7. Surgical treatment of multiple brain metastasis
8. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age
9. A randomized trail of surgery in the treatment of single metastases to the brain
10. A multinstitutional outcome and prognostic factor analysis of radiosurgery for resectable single brain metastasis
11. The role of radiation therapy in the treatment of brain metastases
12. Radiation-induced dementia in patients cured of brain metastases
13. Radiation responce of the central nervous system
14. Penetration of N-(phos-phonacetyl)-L-aspartate into human central nervous system and intracerebral tumor
15. Human central nervous system distrubution of cis-diamminedicholroplatinum and use as a radiosensitizer in malignant brain tumors
16. Response of brain meatstases form lung cancer ot systemic chemotherapy with carboplatin and etoposide
17. Primary chemotherapy of brain metastaiss in small-cell lung cancer
18. Concomitant brain radiotherapy and vinorelbine-ifosfamide-cisplatin chemotherapy in brain metastases of non-small-cell lung cancer
19. Responcse of brain metastases from breast cancer to systemic chemotherapy
20. Activity of temozolomide in the treatment of central nervous system tumor xenografts
21. Preclinical anti tumor activity of temozolomide in mice: Efficacy againt human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea
22. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl- imidazol [5,1-d]1,2,3,5,-tetrazin-4(3H)-one(CCRG 81045; M & B 39831). A novel drug with potnetial as an alternative to dacarbazine
23. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)
24. Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer
25. Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma
26. The Chargingh Cross Hospital experience with temozolomide in patients with gliomas
27. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group
28. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma
29. Optimal two-stage designs for phase II clinical trials
30. Neoplasms of the cetral nervous system
31. Chemotherapy with cisplatin and tenisposide for cerebral metastases in non-small-cell lung cancer
32. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, non-small-cell lung carcinoma, or malignant melanoma: A prospective study
33. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trails
34. Inactivation of O6-alkylguanine-DNA alkyltransferase in HeLa cells by cisplatin
35. A Phase I and pharmacokinetic solid malignancies